COMPLY Investigators. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPLY trial - Mahaffey, KW; Granger, CB; Nicolau, JC (Circulation, 2003)
et al.